WO2010086736A3 - Use of the combination of resveratrol with cysteine and derivatives thereof - Google Patents

Use of the combination of resveratrol with cysteine and derivatives thereof Download PDF

Info

Publication number
WO2010086736A3
WO2010086736A3 PCT/IB2010/000187 IB2010000187W WO2010086736A3 WO 2010086736 A3 WO2010086736 A3 WO 2010086736A3 IB 2010000187 W IB2010000187 W IB 2010000187W WO 2010086736 A3 WO2010086736 A3 WO 2010086736A3
Authority
WO
WIPO (PCT)
Prior art keywords
resveratrol
cysteine
derivatives
combination
nutritional
Prior art date
Application number
PCT/IB2010/000187
Other languages
French (fr)
Other versions
WO2010086736A2 (en
Inventor
Silvia Finzi
Carlo Ghisalberti
Antonio Fiorentino
Original Assignee
Vitrupharma S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT000110A external-priority patent/ITMI20090110A1/en
Priority claimed from IT000779A external-priority patent/ITMI20090779A1/en
Application filed by Vitrupharma S.R.L. filed Critical Vitrupharma S.R.L.
Publication of WO2010086736A2 publication Critical patent/WO2010086736A2/en
Publication of WO2010086736A3 publication Critical patent/WO2010086736A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0216—Solid or semisolid forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a novel use of nutritional/pharmaceutical compositions comprising as active ingredients resveratrol and cysteine and derivatives thereof. More specifically, the invention relates to the use of such nutritional/pharmaceutical compositions for treating and/or preventing a hyaluronidase-related disorder such as skin senescence or joint arthritis, in particular in postmenopausal women.
PCT/IB2010/000187 2009-01-30 2010-02-01 Novel use of the combination of resveratrol with cysteine and derivatives thereof WO2010086736A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IT000110A ITMI20090110A1 (en) 2009-01-30 2009-01-30 NEW USE OF A RESVERATROL COMBINATION OR ITS ANALOGUE USE AND THE CISTEIN OR ITS DERIVATIVE
ITMI2009A000110 2009-01-30
IT000779A ITMI20090779A1 (en) 2009-05-08 2009-05-08 NUTRITIONAL COMPOSITIONS BASED ON CISTEIN RESVERATROL OR ITS DERIVATIVES OR METABOLITES AND ASTAXANTIN
ITMI2009A000779 2009-05-08

Publications (2)

Publication Number Publication Date
WO2010086736A2 WO2010086736A2 (en) 2010-08-05
WO2010086736A3 true WO2010086736A3 (en) 2010-09-23

Family

ID=42315761

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2010/000187 WO2010086736A2 (en) 2009-01-30 2010-02-01 Novel use of the combination of resveratrol with cysteine and derivatives thereof

Country Status (1)

Country Link
WO (1) WO2010086736A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017100368A4 (en) * 2016-09-23 2017-05-18 The University Of Newcastle Methods for improving cerebrovascular function and cognition in peri- and post-menopausal women

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1364943A1 (en) * 2001-02-02 2003-11-26 Ajinomoto Co., Inc. Novel cystine derivatives and inhibitors for the activation of inflammatory factors
US20050048008A1 (en) * 2003-08-29 2005-03-03 Bioderm Research Antiaging Cosmetic Delivery Systems
US20050107338A1 (en) * 2003-11-17 2005-05-19 Seidman Michael D. Nutritional supplement enhancing mitochondrial function
US7105570B2 (en) * 1998-10-09 2006-09-12 Ajinomoto Co., Inc. Cysteine derivatives
US20060257502A1 (en) * 2005-05-11 2006-11-16 Jiankang Liu A combination of mitochondrial nutrients for relieving stress, preventing and improving stress-related disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2777186B1 (en) 1998-04-10 2001-03-09 Oreal USE OF AT LEAST ONE HYDROXYSTILBENE IN A FIRMING COMPOSITION
FR2796278B1 (en) 1999-07-16 2002-05-03 Oreal USE OF AT LEAST ONE HYDROXYSTILBENE AS AN ANTI-GLYCATION AGENT
US20060270732A1 (en) 2005-05-26 2006-11-30 Suracell, Inc. Antioxidant supplement compostion and method of use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105570B2 (en) * 1998-10-09 2006-09-12 Ajinomoto Co., Inc. Cysteine derivatives
EP1364943A1 (en) * 2001-02-02 2003-11-26 Ajinomoto Co., Inc. Novel cystine derivatives and inhibitors for the activation of inflammatory factors
US20050048008A1 (en) * 2003-08-29 2005-03-03 Bioderm Research Antiaging Cosmetic Delivery Systems
US20050107338A1 (en) * 2003-11-17 2005-05-19 Seidman Michael D. Nutritional supplement enhancing mitochondrial function
US20060257502A1 (en) * 2005-05-11 2006-11-16 Jiankang Liu A combination of mitochondrial nutrients for relieving stress, preventing and improving stress-related disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BAXTER R A: "Anti-aging properties of resveratrol: Review and report of a potent new antioxidant skin care formulation", JOURNAL OF COSMETIC DERMATOLOGY 200803 GB, vol. 7, no. 1, March 2008 (2008-03-01), pages 2 - 7, XP008111451 *
CSAKI ET AL: "Regulation of inflammation signalling by resveratrol in human chondrocytes in vitro", BIOCHEMICAL PHARMACOLOGY, PERGAMON, OXFORD, GB, vol. 75, no. 3, 11 January 2008 (2008-01-11), pages 677 - 687, XP022418015, ISSN: 0006-2952 *
SHAKIBAEI M ET AL: "Resveratrol suppresses interleukin-1beta-induced inflammatory signaling and apoptosis in human articular chondrocytes: Potential for use as a novel nutraceutical for the treatment of osteoarthritis", BIOCHEMICAL PHARMACOLOGY, PERGAMON, OXFORD, GB, vol. 76, no. 11, 1 December 2008 (2008-12-01), pages 1426 - 1439, XP025673411, ISSN: 0006-2952, [retrieved on 20080603] *

Also Published As

Publication number Publication date
WO2010086736A2 (en) 2010-08-05

Similar Documents

Publication Publication Date Title
IN2014KN01664A (en)
WO2011148328A3 (en) Cosmetic process for making-up and/or caring for the skin and/or the lips
WO2011061330A3 (en) Use of physiological cooling active ingredients, and agents containing such active ingredients
WO2010000877A3 (en) Formulation with irritation reducing action comprising bisabolol and [6]-paradol
CA2863681A1 (en) Topical use of a skin-commensal prebiotic agent and compositions containing the same
WO2011073437A3 (en) Bacteriocin- and prebiotic-based cosmetic or dermatological compositions
WO2013178965A3 (en) Active ingredients activating mitophagy in skin cells and use of same for improving skin condition
WO2010092088A3 (en) Use of hydrophobin as a spreading agent
WO2010021607A3 (en) Pharmaceutical formulation
WO2011049327A3 (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
WO2011000866A3 (en) Multicomponent glasses for use in personal care products
MX342947B (en) Treatment of type 2 diabetes.
WO2011043631A3 (en) Pharmaceutical composition for preventing and treating cold, containing reynoutria elliptica extract, fraction thereof or stilbene-based compound
WO2012002730A3 (en) Skin-whitening and skin-moisturizing composition containing bee venom extracts
MX357554B (en) Aloe vera sprout concentrate or extract having superior skin cell growth promotion, antioxidant, and anti-allergy effects.
WO2012161497A3 (en) Peptide derivatives having a superior moisturizing effect and uses thereof
WO2010094975A3 (en) Solid cosmetic composition comprising cream of tartar
WO2010046061A3 (en) Cosmetic and/or pharmaceutical formulations
MX2010002812A (en) Food compositions comprising lemon balm extracts.
WO2012084336A3 (en) Hair treatment products containing one or more surfactant(s) and one or more cationic keratin hydrolysate(s)
TW201129394A (en) Composition for inhibiting melanogenesis and use thereof
WO2013170086A3 (en) Formulations for the delivery of active ingredients
WO2011139252A3 (en) Efervescent formulations comprising cefdinir
MX2014006574A (en) Acamprosate formulations, methods of using the same, and combinations comprising the same.
WO2013000895A9 (en) Dha and epa in the reduction of oxidative stress

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10704978

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10704978

Country of ref document: EP

Kind code of ref document: A2